• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2001 Fiscal Year Final Research Report Summary

Study on the regulation mechanism of proliferation and differentiation of human prostatic stromal cells: Effects of TGF-βs on human prostatic myofibroblast and α-adrenergic receptor.

Research Project

Project/Area Number 11671566
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Urology
Research InstitutionSapporo Medical University

Principal Investigator

TAKAHASHI Satoshi  Sapporo Medical University School of medicine, Senior Instructor, 医学部, 助手 (30332919)

Co-Investigator(Kenkyū-buntansha) TAKAHASHI Atsushi  Sapporo Medical University School of Medicine, Senior Instructor, 医学部, 助手 (20274946)
MASUMORI Naoya  Sapporo Medical University School of Medicine, Assistant Professor, 医学部, 講師 (20295356)
ITOH Naoki  Sapporo Medical University School of Medicine, Associate Professor, 医学部, 助教授 (60193504)
KUNISHIMA Yasuharu  Sapporo Medical University School of Medicine, Senior Instructor, 医学部, 助手 (00315508)
SASAMURA Hiroto  Sapporo Medical University School of Medicine, Senior Instructor, 医学部, 助手 (50311890)
Project Period (FY) 1999 – 2001
KeywordsBenign prostatic hyperplasia / Prostatic stroma / Myofibroblast / Smooth muscle / TGF-β / α1 receptor
Research Abstract

In order to study the effects of TGF-βs on human prostatic stromal cells, we purified human prostatic myofibroblast using specimens that was taken by operations and established culture system of these cells. These cells were immunohistochemically recognized as myofibroblast according to the findings of positive staining of a-smooth muscle actin and negative staining of both myosin and desmin. The expressions of TCF-β receptor I, II mRNA were confirmed by RT-PCR in these cells. After the treatment of various concentrations of human TGF-β1, 2, 3, it was recognized that these cells expressed both myosin and desmin. These findings suggested that TGF-βs could differentiate myofibroblast to smooth muscle. On the other hand, TGF-β1, 2, 3 inhibited proliferation of myofibroblast by dose-dependent manner.
It has been well known that there are three subtypes of α1-receptor in human prostatic tissue; 1a, 1b and 1d, however the distribution of these subtypes in myofibroblast and smooth muscle cells … More has not been clarified. Using myofibroblast that was established by us and human prostatic smooth muscle that was commercially available, the expressions of 1a, 1b, 1d subtype mRNA were quantitatively analyzed by real time RT-PCR. The expression of 1a was recognized in smooth muscle only, and both 1b and 1d were determined in myofibroblast and smooth muscle cells. Based on these findings, it was speculated that the expression of ala receptor mRNA was induced during the differentiation from myofibroblast to smooth muscle.
To clarify the effect of TGF-β1 on the expression of α1 receptor in myofibroblast and smooth muscle, the expressios of α1a, 1b, 1d receptor mRNA were quantitatively analyzed by real time RT-PCR. Moreover, α1 receptor binding assay was performed using [^<125 >I] HEAT as a ligand. The expression of ala was detected in these cells cultured under the condition without TGF-β1. The expressions of 1b and 1d without TGF-β were significantly higher 0.13 and 0.09 times respectively than with TGF-β1. Bmax of [^^<125>I]HEAT (300pM) was 37.5 fmol/mg protein in the medium without TGF-β1 and 21.3fmol/mg protein in those with TGF-β1.
It was concluded that TGF-βs could have human prostatic myofibroblast differentiate to smooth muscle cell. On the other hand, the function of smooth muscle was undifferentiated by TGF-β1, because the expression of al receptor was suppressed by it. Based on these results, it was speculated that the regulatory mechanisms of morphological differentiation might be different from these of functional differentiation in human prostatic stroma. Less

  • Research Products

    (14 results)

All Other

All Publications (14 results)

  • [Publications] Tanaka Y, Masumori N, Itoh N, et al.: "Symptomatic and urodynamic improvement by oral distigmine bromide in poor boiders after transurethral resection of the prostate"Urology. 57. 270-274 (2000)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 伊藤直樹: "前立腺のホルモン調節と効果発現の機序"Modern Physician. 21. 1182-1183 (2001)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 塚本泰司, 舛森直哉, 伊藤直樹: "前立腺肥大症"臨床成人病. 31. 757-761 (2001)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 伊藤直樹: "排尿症状をどうとらえるか"腎と透析. 51. 757-761 (2001)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 田中吉則, 舛森直哉, 伊藤直樹ほか: "前立腺推定容積、最大尿流率、残尿量およびI-PSSによる下部尿路閉塞の推定"泌尿紀要. 47. 843-847 (2001)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Tanaka Y, Masumori N, Itoh N, Sato Y, Takahashi A, et al.: "Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia"Journal of Urology. (in press). (2002)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Furuya S, Itoh N, Tsukamoto T, et al.: ""Recent Advances in Endocrinology 2 Treatment of Benign Prostatic Hyperplasia",Ed. by Koshiba K, et al."Transurethral balloon laser thermotherapy for treatment of benign prostatic hyperplasia. 10 (2000)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Tanaka .Y, Masumori N., Itoh N., Furuya S., et al.: "Symptomatic and urodynamic improvement by oral distigmine bromide in poor voiders after transurethral resection of the prostate"Urology. 57. 270-274 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Furuya S., Itoh N., Tsukamoto T., et al.: "Transurethral balloon laser thermotherapy for treatment of benign prostatic hyperplasia"Recent Advances in Endocrinology 2 Treatment of Benign Prostatic Hyperplasia,Ed. by Koshiba K, et al, pp.71-80, The Japanese Society of Endourology and ESWL 2000..

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tanaka Y., Masumori N., Itoh N., Tsukamoto T.: "The prediction of bladder outlet obstruction with prostate volume, maximum flow rate, residual urine and the international prostate symptom score in patients with lower urinary tract symptoms (in Japanese)"Acta Urol. Jpn.. 47. 843-847 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tsukamoto T, Masumori N, Itoh N.: "BPH-Other medical therapie(in Japanese)"Voiding Disorders Digest. 9. 66-70 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tsukamoto T., Masumori T., Itoh N.: "Benign prostatic hyperplasia (inJapanese)"Rinsho Seijinbyo. 31. 195-200 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Itoh N.: "Measuring the symptoms of benign prostatic hyperplasia (in Japanese)"JIn to Toseki. 51. 757-761 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tanaka Y., Masumori N., Itoh N, Sato Y., Takahashi A., et al.: "Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia"Journal of Urology. (in press). (2002)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2003-09-17  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi